國家衛生研究院 NHRI:Item 3990099045/6903
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 914485      線上人數 : 1391
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/6903


    題名: Early data from a phase I study of nintedanib (BIBF1120) in Asian patients with advanced hepatocellular carcinoma
    作者: Yen, C;Shen, Y;Shiah, H;Chen, J;Hsu, C;Huang, DC;Hocke, J;Su, W;Cheng, A
    貢獻者: National Institute of Cancer Research
    摘要: Background: Nintedanib is an oral, triple angiokinase inhibitor targeting VEGFRs, PDGFRs and FGFRs. This multicentre, open-label, phase I/randomised phase II study (NCT00987935; phase II ongoing) evaluated the efficacy, safety and pharmacokinetics of nintedanib versus sorafenib in patients ( pts) with advanced hepatocellular carcinoma (HCC) from Asia, where HCC is endemic and has unique clinical features. Phase I data are presented. Methods: Phase I pts had histologically, cytologically or clinically confirmed HCC, ECOG performance status ?2, Child-Pugh (CP) score ?7, and ?1 line of prior systemic therapy. Using a 3 + 3 design, pts were stratified into two groups by liver function and CP score: (I) AST and ALT ?2 x upper limit of normal (ULN), and CP 5–6; (II) AST or ALT >2 x to ?5 x ULN, or CP 7. Nintedanib (given continuously in 28-day courses) was started at 50mg bid (group II) or 100mg bid (group I) and increased in 50mg bid increments up to 200mg bid. Therapy was continued until no clinical benefit or undue toxicity. The phase I primary endpoint was the maximum-tolerated dose (MTD) of nintedanib. Results: Overall, 35 pts have received nintedanib: 11 in group I(100/150/200 mg bid, n = 4/3/4; median [range] duration: 140 [10–337] days) and 24 in group II (50/100/150/200 mg bid, n = 3/7/3/11; median [range] duration: 81 [2–587] days). In group I, no dose-limiting toxicities (DLTs) were seen at any dose during the first course. In group II, one pt experienced a DLT (CTCAE Grade [G] 3 AST increase) at 100 mg bid in Course 1 (dose-escalation phase). The MTD of nintedanib was thus 200 mg bid in both groups. DLTs seen after MTD assessment were G4 gastrointestinal (GI) haemorrhage/anaemia (50 mg bid), G3 ALT increase (150 mg bid), G3 GI haemorrhage (150 mg bid), G3 hypertension (200 mg bid; n = 2) and G4 gastric ulcer (200 mg bid). The most common adverse events, by system organ class, were GI (83%) and general/administration site disorders (51%), and investigations (51%). Hypertension and rash (any grade) occurred in 6 and 8 pts, respectively. Conclusions: Nintedanib has an acceptable safety profile in this Asian HCC population. As in other cancer types and European HCC pts, the MTD of nintedanib was 200 mg bid.
    日期: 2012-09
    關聯: Annals of Oncology. 2012 Sep;23(Suppl. 9):246-247.
    Link to: http://dx.doi.org/10.1093/annonc/mds398
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0923-7534&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000309409001228
    顯示於類別:[夏和雄(1996-2012)] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000309409001228.pdf1786KbAdobe PDF647檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋